Frontiers in Medicine

Hyperbaric Oxygen Therapy Shows Promise in Addressing Long COVID Pathophysiology, According to Clinical Review Authored by Hyperbaric Medical Solutions Directors

Retrieved on: 
Thursday, February 22, 2024

WOODBURY, N.Y., Feb. 22, 2024 /PRNewswire-PRWeb/ -- A groundbreaking clinical review published in Frontiers in Medicine reveals promising findings on the effectiveness of hyperbaric oxygen therapy (HBOT) in addressing the pathophysiology of long COVID. The study, titled "Hyperbaric Oxygen Effectively Addresses the Pathophysiology of Long COVID: Clinical Review," was authored by the National Medical Director, and the New England Clinical Director of Hyperbaric Medical Solutions, alongside three other esteemed researchers.

Key Points: 
  • A groundbreaking clinical review published in Frontiers in Medicine reveals promising findings on the effectiveness of hyperbaric oxygen therapy (HBOT) in addressing the pathophysiology of long COVID.
  • WOODBURY, N.Y., Feb. 22, 2024 /PRNewswire-PRWeb/ -- A groundbreaking clinical review published in Frontiers in Medicine reveals promising findings on the effectiveness of hyperbaric oxygen therapy (HBOT) in addressing the pathophysiology of long COVID.
  • The study, titled "Hyperbaric Oxygen Effectively Addresses the Pathophysiology of Long COVID: Clinical Review," was authored by the National Medical Director, and the New England Clinical Director of Hyperbaric Medical Solutions, alongside three other esteemed researchers.
  • Hyperbaric Medical Solutions , a leading provider of hyperbaric oxygen therapy, has been at the forefront of treating long COVID patients with positive outcomes.

AeroBand's New Releases Shine at NAMM Show 2024, Garnering Rapid Popularity

Retrieved on: 
Thursday, February 8, 2024

For individuals with finger ailments and sensitivity, including children and the elderly, this breakthrough technology opens up musical possibilities for a wider audience.

Key Points: 
  • For individuals with finger ailments and sensitivity, including children and the elderly, this breakthrough technology opens up musical possibilities for a wider audience.
  • For beginners and those who had previously given up learning the guitar, AeroBand Guitar undoubtedly addresses the pain issue during practice.
  • During the Premier Guitar interview , the AeroBand team showcased a unique application designed specifically for the AeroBand Guitar.
  • At this year's NAMM Show, AeroBand takes the lead and showcases the highly anticipated product - PocketDrum 2 Plus.

ZyVersa Therapeutics Announces a Publication in Frontiers in Medicine Showing Direct Inflammasome Activation in Children with Juvenile Idiopathic Arthritis

Retrieved on: 
Thursday, May 25, 2023

In the paper titled, “Inflammasome activation and formation of ASC specks in patients with juvenile idiopathic arthritis,” the authors reported the following:

Key Points: 
  • In the paper titled, “Inflammasome activation and formation of ASC specks in patients with juvenile idiopathic arthritis,” the authors reported the following:
    Il-1β production from macrophages exposed to extracellular ASC specks was enhanced in serum of JIA patients with a high titer of ANA, suggesting that autoantibodies favor a secondary inflammatory response to ASC specks by macrophages
    The authors stated, “We clearly discovered direct inflammasome activity ex vivo in CD14+ CD16− monocytes of oligo- and poly-articular JIA patients.” To read the article, Click Here .
  • “The research published in Frontiers in Medicine demonstrates the role of inflammasome activation in two of the most common types of JIA, oligo- and poly-articular, which were previously thought to be classical antigen-driven autoimmune conditions.
  • This research provides support for the broad range of conditions that are impacted by activation of the innate immune response,” commented Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO and President.
  • “Additionally, the data demonstrating enhanced IL-1β production from macrophages exposed to extracellular ASC specks in JIA patients with a high titer of ANA supports the potential of ASC speck inhibition in helping to control inflammation in this population.”

Oncoinvent Announces Two Publications in Special Edition of Frontiers in Medicine Focused on Alpha Radioisotopes

Retrieved on: 
Friday, April 21, 2023

Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced the online publication of two articles in the recent special edition of Frontiers in Medicine focused on alpha radioisotopes.

Key Points: 
  • Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced the online publication of two articles in the recent special edition of Frontiers in Medicine focused on alpha radioisotopes.
  • “We are excited to share these compelling and important publications in this special edition of Frontiers in Medicine, which continue to demonstrate that all dose levels of Radspherin® are well tolerated with no dose limiting toxicities to date,” said Jan A. Alfheim, Chief Executive Officer of Oncoinvent.
  • Researchers also collected urine and blood samples post injection to estimate activity concentration of 224Ra and 212Pb.
  • This favorable safety profile in the current study is in line with documentation from other preclinical and clinical studies with other related alpha-emitting compounds administered intraperitoneally.

Aspira Women’s Health Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Wednesday, March 22, 2023

AUSTIN, Texas, March 22, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • Our purpose-driven focus on execution and prudent use of resources will be the key to positioning Aspira as a leader in women’s gynecologic health diagnostics.
  • Continued focus on disciplined spending, reducing cash utilization to $7.1 million in the fourth quarter of 2022, compared to $10.2 million in the first quarter of 2022.
  • Aspira utilized $7.1 million in the fourth quarter of 2022 compared to $7.6 million in the fourth quarter of 2021.
  • Aspira will host a conference call with investors today, March 22, 2023 at 4:30 pm Eastern Time to discuss financial results and provide a corporate update.

New Data Links Modulation of Key Immune-Related Proteins to Improvement of Specific Symptoms in Long COVID

Retrieved on: 
Thursday, February 16, 2023

Data from a new clinical study show modulation of key immune regulating proteins with maraviroc and pravastatin correlates with symptom reduction in patients with post-acute sequelae of COVID (PASC), commonly known as long COVID.

Key Points: 
  • Data from a new clinical study show modulation of key immune regulating proteins with maraviroc and pravastatin correlates with symptom reduction in patients with post-acute sequelae of COVID (PASC), commonly known as long COVID.
  • The study results, published in Frontiers in Medicine, also support a precision medicine approach to diagnosis of long COVID as well as differentiation of long COVID from ME-CFS (myalgic encephalomyelitis/chronic fatigue syndrome), which presents with similar symptoms.
  • Subjective neurological, autonomic, respiratory, cardiac and fatigue symptoms scores all decreased by statistically significant margins.
  • In particular, the FSS (fatigue being the most common symptom) decreased and was closely correlated in decreases of IL-2 and TNF-α.

NexImmune Announces Publication in Frontiers in Medicine Highlighting the Company’s AIM Platform to Treat Viral Diseases

Retrieved on: 
Wednesday, January 18, 2023

Furthermore, T cells generated with the AIM platform are highly polyfunctional and display substantial in vitro cytotoxic activity against respective targeted antigens.

Key Points: 
  • Furthermore, T cells generated with the AIM platform are highly polyfunctional and display substantial in vitro cytotoxic activity against respective targeted antigens.
  • In addition to complications of acute diseases, chronic viral infections are linked to both malignancies and autoimmune disorders.
  • Cells generated by the AIM nanoparticle platform offer a potential treatment modality to address these disorders in a safe and effective manner, utilizing the endogenous immune cells to eliminate virally infected cells.
  • NexImmune is focused on an injectable, off-the-shelf nanoparticle that can activate, tolerize or destroy CD8+ T cells in vivo and continues to move this product toward the clinic.

ABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury

Retrieved on: 
Monday, January 16, 2023

Loreto Gesualdo, full Professor, Head of the Nephrology, Dialysis and Transplantation Unit, University of Bari Aldo Moro, Italy, and lead investigator of the RACERS study stated: “We are incredibly excited to share results from this pilot Phase 2a trial evaluating CER-001 in septic patients at high risk of developing acute kidney injury.

Key Points: 
  • Loreto Gesualdo, full Professor, Head of the Nephrology, Dialysis and Transplantation Unit, University of Bari Aldo Moro, Italy, and lead investigator of the RACERS study stated: “We are incredibly excited to share results from this pilot Phase 2a trial evaluating CER-001 in septic patients at high risk of developing acute kidney injury.
  • There is a complete lack of treatment options for septic patients at high risk of developing acute kidney injury, a disease that in 2019 had an estimated 13.7 million related deaths globally (Lancet 2022; 400: 2221–48).
  • The trial shows promising positive results across a variety of primary and secondary endpoints.
  • The potential use of CER-001 in septic patients is currently under clinical development.

Aspira Women’s Health Announces Preliminary Fourth Quarter 2022 Volume, Preliminary Results in Line with Cash Utilization Guidance, and Other Highlights

Retrieved on: 
Monday, January 9, 2023

AUSTIN, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced preliminary fourth quarter highlights.

Key Points: 
  • Preliminary testing volume during the fourth quarter of 2022 was 5,643, an increase of 18 % compared to the fourth quarter of 2021
    AUSTIN, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced preliminary fourth quarter highlights.
  • The number of OvaSuite tests performed increased 18% to 5,643 tests during the quarter ended December 31, 2022, compared to 4,768 tests for the fourth quarter of 2021.
  • Average daily test volume reached a new high in the fourth quarter, increasing to 86.6.
  • Preliminary results indicate that Aspira has achieved previously provided cash utilization guidance for the fourth quarter of between $6 million and 8 million.

Aspira Women’s Health Announces Publication of Real-World Data Validating Use of OvaWatch for the Management of Adnexal Masses

Retrieved on: 
Friday, January 6, 2023

AUSTIN, Texas, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced its manuscript, entitled: “Validation of deep neural network-based algorithm supporting clinical management of adnexal mass,” has been published in the prestigious peer reviewed journal, Frontiers in Medicine. The paper presents findings from the multi-site clinical study of the company’s new assay, OvaWatch, describing real-world evidence supporting the use of OvaWatch for the clinical management of adnexal masses.

Key Points: 
  • The paper presents findings from the multi-site clinical study of the company’s new assay, OvaWatch, describing real-world evidence supporting the use of OvaWatch for the clinical management of adnexal masses.
  • Conservative management of adnexal masses is warranted when masses are clinically characterized as benign or indeterminate.
  • In this multi-site clinical study, OvaWatch assay, was used to examine malignancy risk in prospective and retrospective samples of patients with an adnexal mass.
  • It is gratifying to see high quality, real-world data confirming and further validating the benefit of using OvaWatch as part of an experienced physician’s treatment planning.